Search Results - "Mainwaring, Paul N."

A digital single-molecule nanopillar SERS platform for predicting and monitoring immune toxicities in immunotherapy by Li, Junrong, Wuethrich, Alain, Sina, Abu A. I., Cheng, Han-Hao, Wang, Yuling, Behren, Andreas, Mainwaring, Paul N., Trau, Matt

“…The introduction of immune checkpoint inhibitors has demonstrated significant improvements in survival for subsets of cancer patients. However, they carry…”
Get full text

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer by Smith, Matthew R, Saad, Fred, Chowdhury, Simon, Oudard, Stéphane, Hadaschik, Boris A, Graff, Julie N, Olmos, David, Mainwaring, Paul N, Lee, Ji Youl, Uemura, Hiroji, Lopez-Gitlitz, Angela, Trudel, Géralyn C, Espina, Byron M, Shu, Youyi, Park, Youn C, Rackoff, Wayne R, Yu, Margaret K, Small, Eric J

“…Among men with nonmetastatic prostate cancer who had a rapid PSA doubling time and were receiving androgen-deprivation therapy, the median metastasis-free…”
Get full text

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial by Choueiri, Toni K, Dr, Escudier, Bernard, MD, Powles, Thomas, Prof, Tannir, Nizar M, Prof, Mainwaring, Paul N, MD, Rini, Brian I, Prof, Hammers, Hans J, MD, Donskov, Frede, MD, Roth, Bruce J, Prof, Peltola, Katriina, MD, Lee, Jae Lyun, Prof, Heng, Daniel Y C, MD, Schmidinger, Manuela, Prof, Agarwal, Neeraj, MD, Sternberg, Cora N, Prof, McDermott, David F, MD, Aftab, Dana T, PhD, Hessel, Colin, MS, Scheffold, Christian, MD, Schwab, Gisela, MD, Hutson, Thomas E, Prof, Pal, Sumanta, MD, Motzer, Robert J, Prof

“…Summary Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR, and AXL. The randomised phase 3 METEOR trial compared the…”
Get full text

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial by Logothetis, Christopher J, Prof, Basch, Ethan, MD, Molina, Arturo, MD, Fizazi, Karim, Prof, North, Scott A, MD, Chi, Kim N, MD, Jones, Robert J, MD, Goodman, Oscar B, MD, Mainwaring, Paul N, MD, Sternberg, Cora N, MD, Efstathiou, Eleni, MD, Gagnon, Dennis D, MA, Rothman, Margaret, PhD, Hao, Yanni, PhD, Liu, Cameron S, PhD, Kheoh, Thian S, PhD, Haqq, Christopher M, MD, Scher, Howard I, Prof, de Bono, Johann S, Prof

“…Summary Background Bone metastases are a major cause of morbidity in metastatic castration-resistant prostate cancer. Abiraterone acetate potently disrupts…”
Get full text

Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial by Basch, Ethan, Dr, Autio, Karen, MD, Ryan, Charles J, MD, Mulders, Peter, Prof, Shore, Neal, MD, Kheoh, Thian, PhD, Fizazi, Karim, Prof, Logothetis, Christopher J, Prof, Rathkopf, Dana, MD, Smith, Matthew R, Prof, Mainwaring, Paul N, MD, Hao, Yanni, PhD, Griffin, Thomas, MD, Li, Susan, PhD, Meyers, Michael L, MD, Molina, Arturo, MD, Cleeland, Charles, Prof

“…Summary Background Abiraterone acetate plus prednisone significantly improves radiographic progression-free survival in asymptomatic or mildly symptomatic,…”
Get full text

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial by Sternberg, Cora N, Dr, Castellano, Daniel, MD, Daugaard, Gedske, Prof, Géczi, Lajos, MD, Hotte, Sebastien J, MD, Mainwaring, Paul N, MD, Saad, Fred, Prof, Souza, Ciro, MD, Tay, Miah H, MD, Garrido, José M Tello, MD, Galli, Luca, MD, Londhe, Anil, PhD, De Porre, Peter, MD, Goon, Betty, BS, Lee, Emma, PhD, McGowan, Tracy, MD, Naini, Vahid, PharmD, Todd, Mary B, DO, Molina, Arturo, MD, George, Daniel J, MD

“…Summary Background In the final analysis of the phase 3 COU-AA-301 study, abiraterone acetate plus prednisone significantly prolonged overall survival compared…”
Get full text

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA by Oudard, Stéphane, Fizazi, Karim, Sengeløv, Lisa, Daugaard, Gedske, Saad, Fred, Hansen, Steinbjørn, Hjälm-Eriksson, Marie, Jassem, Jacek, Thiery-Vuillemin, Antoine, Caffo, Orazio, Castellano, Daniel, Mainwaring, Paul N, Bernard, John, Shen, Liji, Chadjaa, Mustapha, Sartor, Oliver

“…Purpose In patients with metastatic castration-resistant prostate cancer (mCRPC), overall survival (OS) is significantly improved with cabazitaxel versus…”
Get full text

Apalutamide and Overall Survival in Prostate Cancer by Smith, Matthew R., Saad, Fred, Chowdhury, Simon, Oudard, Stéphane, Hadaschik, Boris A., Graff, Julie N., Olmos, David, Mainwaring, Paul N., Lee, Ji Youl, Uemura, Hiroji, De Porre, Peter, Smith, Andressa A., Brookman-May, Sabine D., Li, Susan, Zhang, Ke, Rooney, Brendan, Lopez-Gitlitz, Angela, Small, Eric J.

“…The phase 3 SPARTAN study evaluated apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and…”
Get full text

Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management by Koo, Kevin M., Mainwaring, Paul N., Tomlins, Scott A., Trau, Matt

“…The accurate identification and stratified treatment of clinically significant early-stage prostate cancer have been ongoing concerns since the outcomes of…”
Get full text

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial by Saad, Fred, Cella, David, Basch, Ethan, Hadaschik, Boris A, Mainwaring, Paul N, Oudard, Stéphane, Graff, Julie N, McQuarrie, Kelly, Li, Susan, Hudgens, Stacie, Lawson, Joe, Lopez-Gitlitz, Angela, Yu, Margaret K, Smith, Matthew R, Small, Eric J

“…In the SPARTAN trial, addition of apalutamide to androgen deprivation therapy, as compared with placebo plus androgen deprivation therapy, significantly…”
Get full text

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma by Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Mainwaring, Paul N, Rini, Brian I, Donskov, Frede, Hammers, Hans, Hutson, Thomas E, Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J, Bjarnason, Georg A, Géczi, Lajos, Keam, Bhumsuk, Maroto, Pablo, Heng, Daniel Y.C, Schmidinger, Manuela, Kantoff, Philip W, Borgman-Hagey, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M, Tannir, Nizar M, Motzer, Robert J

“…In a phase 3 clinical trial involving previously treated patients with advanced renal-cell carcinoma, progression-free survival was significantly longer with…”
Get full text

Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars by Stebbing, Justin, Mainwaring, Paul N, Curigliano, Giuseppe, Pegram, Mark, Latymer, Mark, Bair, Angel H, Rugo, Hope S

“…Biosimilars have the potential to broaden patient access to biologics and provide cost savings for health care systems. During the development of a biosimilar,…”
Get full text

Harnessing gene fusion-derived neoantigens for ‘cold’ breast and prostate tumor immunotherapy by Velaga, Ravi, Koo, Kevin M, Mainwaring, Paul N

“…Breast and prostate cancers are generally considered immunologically ‘cold’ tumors due to multiple mechanisms rendering them unresponsive to immune checkpoint…”
Get full text

Design and Clinical Verification of Surface-Enhanced Raman Spectroscopy Diagnostic Technology for Individual Cancer Risk Prediction by Koo, Kevin M, Wang, Jing, Richards, Renée S, Farrell, Aine, Yaxley, John W, Samaratunga, Hema, Teloken, Patrick E, Roberts, Matthew J, Coughlin, Geoffrey D, Lavin, Martin F, Mainwaring, Paul N, Wang, Yuling, Gardiner, Robert A, Trau, Matt

“…The use of emerging nanotechnologies, such as plasmonic nanoparticles in diagnostic applications, potentially offers opportunities to revolutionize disease…”
Get full text

Toward Precision Medicine: A Cancer Molecular Subtyping Nano-Strategy for RNA Biomarkers in Tumor and Urine by Koo, Kevin M., Wee, Eugene J. H., Mainwaring, Paul N., Wang, Yuling, Trau, Matt

“…Cancer is a heterogeneous disease which manifests as different molecular subtypes due to the complex nature of tumor initiation, progression, and metastasis…”
Get full text

Phosphoprotein Biosensors for Monitoring Pathological Protein Structural Changes by Ahmed, Mostak, Koo, Kevin M., Mainwaring, Paul N., Carrascosa, Laura G., Trau, Matt

“…Current biotechnological developments are driving a significant shift towards integrating proteomic analysis with landmark genomic, methylomic, and…”
Get full text

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial by Cella, David, Escudier, Bernard, Tannir, Nizar M, Powles, Thomas, Donskov, Frede, Peltola, Katriina, Schmidinger, Manuela, Heng, Daniel Y C, Mainwaring, Paul N, Hammers, Hans J, Lee, Jae Lyun, Roth, Bruce J, Marteau, Florence, Williams, Paul, Baer, John, Mangeshkar, Milan, Scheffold, Christian, Hutson, Thomas E, Pal, Sumanta, Motzer, Robert J, Choueiri, Toni K

“…Purpose In the phase III METEOR trial ( ClinicalTrials.gov identifier: NCT01865747), 658 previously treated patients with advanced renal cell carcinoma were…”
Get full text

A simple, rapid, low-cost technique for naked-eye detection of urine-isolated TMPRSS2:ERG gene fusion RNA by Koo, Kevin M., Wee, Eugene J. H., Mainwaring, Paul N., Trau, Matt

“…The TMPRSS2:ERG gene fusion is one of a series of highly promising prostate cancer (PCa) biomarker alternatives to the controversial serum PSA. Current methods…”
Get full text

Cancer Therapy: Toward Precision Medicine: A Cancer Molecular Subtyping Nano-Strategy for RNA Biomarkers in Tumor and Urine (Small 45/2016) by Koo, Kevin M., Wee, Eugene J. H., Mainwaring, Paul N., Wang, Yuling, Trau, Matt

“…Cancer is a heterogeneous disease manifesting as a variety of intricate subtypes that require different treatment strategies. On page 6233, E. J. H. Wee, Y…”
Get full text

Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-acetic acid) to Docetaxel in CRMPC by PILI, Roberto, ROSENTHAL, Mark A, MAINWARING, Paul N, VAN HAZEL, Guy, SRINIVAS, Sandy, DREICER, Robert, GOEL, Sanjay, LEACH, Joseph, WONG, Shirley, CLINGAN, Peter

“…This randomized phase II study evaluated ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) in combination with docetaxel in castration-refractory…”
Get full text